Doug Lauffenburger
![]() | This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these template messages)
|
Douglas A. Lauffenburger is an American academic who is the Ford Professor of Biological Engineering, Chemical Engineering, and Biology at the Massachusetts Institute of Technology (since 2009). He is a member of the David H. Koch Institute for Integrative Cancer Research and MIT Center for Gynepathology Research as well as an Affiliate, The Ragon Institute of MIT, MGH and Harvard.[1] He is also editor in chief of the journal Integrative Biology.[2]
Lauffenburger’s lab “emphasizes integration of experimental and mathematical/computational analysis approaches, toward development and validation of predictive models for physiologically-relevant behavior in terms of underlying molecular and molecular network properties.”[3]
He is also one of six MIT professors elected as a fellow of the American Association for the Advancement of Science (AAAS).[4]
Biography[edit]
Lauffenburger earned a B.S. in Chemical Engineering from the University of Illinois and a Ph.D. in Chemical Engineering from the University of Minnesota.[1]
Lauffenburger was a professor at the University of Illinois and the University of Pennsylvania and a visiting professor at the University of Wisconsin before his tenure at MIT. He was a visiting scientist at the University of Heidelberg in Germany.[1]
At MIT, he has been a Professor at the Department of Biological Engineering since 1998 and was then Head,[5] 1998-2019; Professor, Department of Chemical Engineering, 1995-present; Professor, Department of Biology, 2002-present.[6][7]
In February 2021 Lauffenburger co-authored a paper in Nature Communications on how a certain level of COVID-19 anti-bodies may provide lasting protection against the virus. The paper was based on blood samples provided voluntarily by 4300 employees of SpaceX crediting also its CEO Elon Musk.[8][9]
References[edit]
- ^ a b c "Douglas A. Lauffenburger, PhD". Biological Engineering. MIT. Retrieved 19 November 2020.
- ^ "Integrative Biology". Oxford University Press. Retrieved 19 November 2020.
- ^ "Doug Lauffenburger Research Group". MIT. Retrieved 19 November 2020.
- ^ "Six MIT faculty elected 2019 AAAS Fellows". MIT News Office. November 26, 2019. Retrieved 21 February 2021.
- ^ Wolfson, John (June 24, 2007). "When Race Enters the Equation". Boston Magazine. Retrieved 21 February 2021.
- ^ "Doug Lauffenburger : Research Group". MIT. Retrieved 19 November 2020.
- ^ Zhong, Vivian (April 18, 2019). "Doug Lauffenburger reflects on time as inaugural biological engineering department head". The Tech. Retrieved 19 November 2020.
- ^ Krouse, Sarah (2021-02-21). "Elon Musk got 4,000 SpaceX workers to join a COVID-19 study. Here's what he learned". Wall Street Journal. Retrieved 2021-02-21 – via foxbusiness.com.
- ^ Bartsch, Yannic C.; Fischinger, Stephanie; Siddiqui, Sameed M.; Chen, Zhilin; Yu, Jingyou; Gebre, Makda; Atyeo, Caroline; Gorman, Matthew J.; Zhu, Alex Lee; Kang, Jaewon; Burke, John S.; Slein, Matthew; Gluck, Matthew J.; Beger, Samuel; Hu, Yiyuan; Rhee, Justin; Petersen, Eric; Mormann, Benjamin; de St Aubin, Michael; Hasdianda, Mohammad A.; Jambaulikar, Guruprasad; Boyer, Edward W.; Sabeti, Pardis C.; Barouch, Dan H.; Julg, Boris D.; Musk, Elon R.; Menon, Anil S.; Lauffenburger, Douglas A.; Nilles, Eric J.; Alter, Galit (2021-02-15). "Discrete SARS-CoV-2 antibody titers track with functional humoral stability". Nature Communications. 12 (1): 1018. doi:10.1038/s41467-021-21336-8. PMC 7884400. PMID 33589636.